Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00739960 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Abatacept to Treat Refractory Sarcoidosis
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00739960 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 1 participants.
The verdict
NCT00739960, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how safe and effective Abatacept is in treating patients who have progressive pulmonary sarcoidosis.
Interventions
- DRUG Abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2008-08 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00739960
The ClinicalTrials.gov registry entry for NCT00739960 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abatacept is the first listed.
NCT00739960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00739960 about?
NCT00739960 is a clinical study titled "Safety Study of Abatacept to Treat Refractory Sarcoidosis". The purpose of this study is to determine how safe and effective Abatacept is in treating patients who have progressive pulmonary sarcoidosis.
What is the current status of trial NCT00739960?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2008-08. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00739960?
The interventions under investigation include: Abatacept (DRUG).
Who is sponsoring clinical trial NCT00739960?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.